Neurosecretion involves fusion of vesicles with the plasma membrane. Such membrane fusion is mediated by the SNARE complex, which is composed of the vesicle-associated protein synaptobrevin (VAMP2), and the plasma membrane proteins syntaxin-1A and SNAP-25. Although clearly important at the point of membrane fusion, the precise structural and functional requirements for the transmembrane domains (TMDs) of SNAREs in bringing about neurosecretion remain largely unknown. Here, we used a bimolecular fluorescence complementation (BiFC) approach to study SNARE protein interactions involving TMDs in vivo. VAMP2 molecules were found to dimerise through their TMDs in intact cells. Dimerisation was abolished when replacing a glycine residue in the centre of the TMD with residues of increasing molecular volume. However, such mutations still were fully competent in bringing about membrane-fusion events, suggesting that dimerisation of the VAMP2 TMDs does not have an important functional role. By contrast, a series of deletion or insertion mutants in the C-terminal half of the TMD were largely deficient in supporting neurosecretion, whereas mutations in the N-terminal half did not display severe secretory deficits. Thus, structural length requirements, largely confined to the C-terminal half of the VAMP2 TMD, seem to be essential for SNARE-mediated membrane-fusion events in cells.
Introduction
Intracellular membrane-fusion events require a conserved set of proteins designated SNAREs [soluble N-ethyl maleimide-sensitive factor (NSF) attachment protein receptors] (Lin and Scheller, 2000; Jahn et al., 2003; Wickner and Schekman, 2008; Chernomordik and Kozlou, 2008) . The best characterised SNAREs are those mediating neurotransmitter release, and include the C-terminally anchored integral membrane protein synaptobrevin2 (VAMP2) on the vesicular membrane, as well as two proteins on the plasma membrane, the C-terminally anchored integral membrane protein syntaxin-1A and the peripherally-associated membrane protein synaptosome-associated protein of 25 kDa (SNAP-25) (Ungar and Hughson, 2003; Jahn and Scheller, 2006) . These three proteins form a stable ternary trans SNARE complex that bridges the opposing vesicular and plasma membranes before the actual fusion event and mediates membrane fusion in vitro upon reconstitution of the proteins into liposomes (Lin and Scheller, 1997; Hanson et al., 1997; Weber et al., 1998; Poirier et al., 1998; Sutton et al., 1998; Rizo and Rosenmund, 2008) .
Higher-order SNARE complex multimers seem to be required for efficient membrane fusion in intact cells (Stewart et al., 2000; Hua and Scheller, 2001; Han et al., 2004; Montecucco et al., 2005) . Distinct molecular interactions responsible for oligomerisation of SNARE complexes have been reported (Littleton et al., 2001; Tokumaru et al., 2001; Kweon et al., 2002; Rickman et al., 2005; Fdez et al., 2008) , including interactions mediated by the transmembrane domains (TMDs). For example, self-interaction of the syntaxin-1A TMDs has been proposed to have a scaffolding role for the subsequent formation of a supramolecular SNARE complex at the fusion site (Lu et al., 2008) , or to be implicated in mediating the transition from a hemifusion to a full-fusion state (Hofmann et al., 2006) .
Recent crystallographic studies of full-length SNARE complexes indicate that the TMD of VAMP2 is -helical, and tightly packs against the TMD of syntaxin-1A along the N-terminal half, whereas the C-terminal parts of the TMDs steer away from each other . Although the structure probably reflects that of a cis SNARE complex, it nevertheless indicates differences in packing interactions between the N-terminal and C-terminal halves of the TMDs.
TMD interactions of SNARE proteins not incorporated into complexes might also occur. For example, individual VAMP2 or syntaxin-1A molecules have been reported to form TMD-mediated homodimers and heterodimers in a sequence-specific manner (Laage and Langosch, 1997; Margittai et al., 1999; Laage et al., 2000; Fleming and Engelman, 2001a; Kroch and Fleming, 2006; Tong et al., 2009 ). However, the relative affinity of such interactions has been controversial (Bowen et al., 2002; Roy et al., 2004) , and their in vivo relevance remains unclear, given that all studies have been performed in vitro in detergent solution or in liposomes. In addition, although the crucial importance of the TMD of SNAREs for membrane fusion events is recognised (Langosch et al., 2007) , the precise structural and functional requirements for the TMD, especially in intact cells, are largely unknown.
In this work, we attempt to determine functionally important features of the VAMP2 TMD, and correlate TMD interactions between VAMP2 molecules to SNARE-mediated fusion activity. A bimolecular fluorescence complementation (BiFC) assay (Kerppola, 2006; Kerppola, 2008) VAMP2 interact, with a glycine residue in the centre having an important role. Using a toxin-rescue secretion assay in neuroendocrine cells, we found that mutations that abolished TMD interactions had no effect on neurosecretion, indicating that such interactions are not relevant to the fusion activity of the v-SNARE protein. However, secretory deficits were observed with a set of mutations affecting the length of the TMD, and were more pronounced when introduced at the C-terminal half, as compared with the N-terminal half. Thus, structural length requirements at the C-terminal half of the VAMP2 TMD seem to be crucially important for bringing about SNARE-mediated neurosecretion.
Results

Dimerisation of VAMP2 molecules in intact cells as visualised by BiFC
To probe for interactions between SNARE proteins in intact cells, we co-expressed two VAMP2 fusion proteins, each tagged at the C-terminus with complementary, nonfluorescent fragments of Venus, a temperature-insensitive GFP variant (Shyu et al., 2006; Shyu et al., 2008) . Reconstitution of the fluorophore provides an indirect measure of interactions between two VAMP2 molecules covalently linked to each fragment (Fig. 1A) . Neuroendocrine PC12 cells were co-transfected with the two fusion proteins, and a VAMP2-BiFC signal was observed in live cells as well as upon fixation (Fig. 1B,C ). VAMP2-BiFC was detected in neuritic processes, where it largely overlapped with the vesicle marker synaptotagmin, as well as in a perinuclear compartment largely overlapping with a trans-Golgi marker (Fig. 1C) . The BiFC signal specifically reflected VAMP2 interactions, because only occasional, weak cytosolic BiFC was observed when the two halves of Venus were used on their own (Fig. 1C) . The subcellular localisation of VAMP2-BiFC matched the localisation of C-terminally GFP-tagged VAMP2, as well as that of endogenous VAMP2 (supplementary material Fig. S1 ), indicating that it was not due to aberrant localisation of tagged, overexpressed proteins. In addition, tagging the C-termini of synaptotagmin did not result in BiFC (not shown), even though both tagged fragments were expressed, as assessed by western blotting (supplementary material Fig. S2 ), suggesting that the VAMP2 BiFC signal was not merely a result of overexpressing a synaptic vesicle protein. When the C-termini of two syntaxin-1A molecules were tagged with Venus fragments, BiFC was observed at the plasma membrane in a non-even patchy manner (supplementary material Fig. S3 ), whereas BiFC of VAMP2-syntaxin-1A was more homogeneously distributed across the plasma membrane (supplementary material Fig. S4 ). Thus, the intracellular distribution of VAMP2-BiFC most probably reflects homotypic interactions between individual non-complexed VAMP2 molecules, rather than the presence of dimeric trans SNARE complexes (Fig. 1D ).
Dimerisation of VAMP2 is mediated by the TMDs
The sequences responsible for the interaction between VAMP2 molecules were next probed with a series of deletion mutants ( Fig.  2A ). VAMP2 harbours a synaptic-vesicle-targeting signal, and distinct mutations of this signal either enhanced its presence in the plasma membrane or in intracellular structures (supplementary material Fig. S5 ), as previously described (Grote et al., 1995; Grote and Kelly, 1996) . Deletion of the SNARE coiled-coil domain, or of the entire cytoplasmic domain of VAMP2 prevented trafficking of such mutants out of a trans-Golgi compartment ( Fig.  2A,B) . However, these truncated mutants still displayed BiFC (Fig.  2C,D 
A glycine residue is crucial for TMD-mediated interactions
Careful inspection of the sequences of the VAMP2 TMD in different species indicated the largely conserved presence of a glycine residue (G100) in the centre of the TMD (Fig. 3A) . Glycine residues in TMDs have been shown to have important structural roles in a variety of transmembrane proteins, with a high occurrence at helix crossing points (Lemmon et al., 1994; MacKenzie et al., 1997; Burke et al., 1997; Javadpour et al., 1999; Fleming and Engelman, 2001b) . We next probed for the importance of molecular volume and flexibility at this position (Fig. 3B ). For this purpose, the glycine residue was replaced by amino acids of increasing molecular volume (Y>V>A>G) (Zamyatnin, 1972; Szule and Coorssen, 2004) . All mutants were found to be overexpressed to similar degrees, and to be properly localised and largely co-localised with synaptotagmin in neuritic processes (supplementary material Fig. S6 ). Interestingly, although the G100A mutant still displayed fluorescence complementation (Fig. 3C ), no complementation was observed with G100V or G100Y mutants (Fig. 3D) . Lack of complementation with the G100V or G100Y mutants was not due to a lack of co-expression ( Fig. 3D ,E). Furthermore, a combination of G100V and wild-type VAMP2 did give BiFC (Fig. 3C ), whereas a combination of G100Y and wild-type VAMP2 did not. Finally, mutation of the glycine to a proline residue, which is reported to induce helix distortion and/or dynamically flexible hinges (Cordes et al., 2002) , resulted in BiFC (Fig. 3C ). Together, these data indicate an important role for a glycine residue in VAMP2 TMD interactions.
TMD-mediated VAMP2 interactions are not important for neurosecretion
We next evaluated whether the observed TMD-mediated VAMP2 interactions are important for membrane fusion events. For this purpose, neuroendocrine PC12 cells were transfected with a plasmid containing both non-tagged VAMP2 and human growth hormone (hGH) (Fdez et al., 2008) . Cells were permeabilised and treated with recombinant botulinum neurotoxin type F light-chain (botF/LC), which cleaves and inactivates VAMP2 (Fig. 4A ). As expected, Ca
2+
-dependent secretion of hGH was decreased (to 27% of control). The expression of botF/LC-resistant VAMP2 (K59R) (Schmidt and Stafford, 2005) restored secretion (102% of 2475 SNARE transmembrane domain and fusion control) in the presence of toxin (Fig. 4B ). This rescue assay was then used to measure the ability of VAMP2 TMD mutants to support exocytosis in the absence of endogenous protein. Surprisingly, none of the glycine mutants with increased molecular volume, including mutants that abolished TMD-mediated interactions as assessed by BiFC, displayed any effect on neurosecretion (Fig. 4C) ; mutation of the glycine to a proline residue slightly enhanced secretion (Fig. 4C) . Finally, we also mutated a series of residues previously described to contribute in vitro to an interaction interface for VAMP2 TMDs (Laage and Langosch, 1997; Margittai et al., 1999; Laage et al., 2000; Fleming and Engelman, 2001a; Kroch and Fleming, 2006; Tong et al., 2009) (Fig. 4D) . These mutants were overexpressed to similar degrees as wild-type VAMP2 and properly localised (supplementary material Fig. S6) ; they still displayed BiFC (Fig. 4E ) and did not show secretory deficits (Fig. 4C) . Thus, TMD-mediated interactions between VAMP2 as measured by BiFC do not seem to have an important role in neurosecretion in intact cells.
The C-terminal half of the VAMP2 TMD is functionally important
It is well established that the SNARE TMDs have an important role in bringing about membrane-fusion events (Grote et al., 2000; McNew et al., 2000; Han et al., 2004; Langosch et al., 2007) . To more precisely map the functionally important regions, we generated a series of N-terminal or C-terminal deletion and insertion mutants (Fig. 5A) . Exogenous, non-tagged VAMP2 was expressed at around four times over endogenous levels, and all mutants analysed were expressed to similar degrees (supplementary material Fig. S6 ). We next determined the subcellular localisation of all mutants as GFPfusion proteins ( Fig. 5B; supplementary material Fig. S6 ). Deletion of three residues at the N-terminus (d97-99), or three (d114-116) or five (d112-116) residues at the C-terminus resulted in VAMP2 mutants that were properly localised to neuritic processes, whereas a mutant lacking six residues (d111-116) at the C-terminus was colocalised with synaptotagmin to a lesser degree, and a mutant lacking seven residues at the C-terminus (d110-116) was retained in a perinuclear compartment ( Fig. 5B; supplementary material Fig. S6 ). Conversely, insertion of three residues at the N-terminal (M96+3L) or C-terminal (I108+3L) half of the VAMP2 TMD did not alter intracellular localisation, whereas insertion of six residues at the Nor C-terminus of the TMD (M96+6L, I108+6L) resulted in additional punctate intracellular localisation ( Fig. 5B ; supplementary material Fig. S6 ). All mutants that were properly localised displayed similar predicted negative apparent free-energy values for insertion of the TMD into the ER membrane, indicating that they are all likely to be properly recognised as a TMD helix and integrated into the membrane (supplementary material Fig. S7 ). VAMP2 TMD mutants that were properly localised were then analysed for their ability to support membrane fusion. All toxin-insensitive C-terminal truncation or insertion mutants were severely impaired in their ability to rescue secretion (Fig. 5C ). By contrast, truncation or insertion mutants at the N-terminal half of the VAMP2 TMD had no or little effect (Fig.  5C ). Similarly, deletion of a short region proposed to induce a kink ahead of the TMD (Kweon et al., 2003) (dLK/dNLK), had no effect on the extent of neurosecretion (Fig. 5C ). The d110-116 mutant did not rescue neurosecretion, in agreement with its mislocalisation to the TGN area, and secretory deficits were also observed with the partially mislocalised six-residue insertion mutants (M96+6L, I108+6L) (supplementary material Fig. S8) . Altogether, the data 2476 Journal of Cell Science 123 (14) , between wild-type (VAMP2-N) and G100V-mutant (G100V-C) (middle), and with G100P mutant (bottom). (D)BiFC (green) with wild-type, but not with G100V or G100Y mutant VAMP2 constructs, co-stained with an anti-myc antibody (blue) and an anti-HA antibody (red) to detect coexpression of BiFC constructs in the same cell. (E)Cells were cotransfected with HA-VAMP2-VenusN and myc-VAMP2-VenusC, or the indicated mutant constructs, followed by SDS-PAGE and western blotting. Similar coexpression of wild-type, G100V and G100Y mutant BiFC constructs was seen, indicating that lack of BiFC with G100V and G100Y is not due to lack of co-expression.
indicate that structural length requirements, especially towards the C-terminal half of the VAMP2 TMD, are essential for SNAREmediated neurosecretion, whereas TMD-mediated interactions, as measured here by BiFC, are without functional implications in this process.
Discussion
Recent studies suggest the importance of several SNARE complexes at the fusion site for successful fusion (Stewart et al., 2000; Hua and Scheller, 2001; Montecucco et al., 2005; Hofmann et al., 2006) . In addition, there is evidence that multimers of syntaxin-1A TMDs are essential for the formation of the fusion pore (Han et al., 2004; Lu et al., 2008) . Although the crucial importance of the syntaxin-1A TMDs for membrane-fusion events is recognised, the precise structural and functional role of the VAMP2 TMD, especially in intact cells, is not well understood.
We used BiFC (Kerppola, 2006; Shyu et al., 2006; Kerppola, 2008; Shyu et al., 2008) to probe for SNARE protein interactions in vivo. Studies of this type showed that VAMP2 molecules dimerise in both a perinuclear compartment, as well as in neuritic processes, and that dimerisation is mediated by their TMDs. Such interactions are not sufficient to escort a truncated VAMP2 molecule that interacts with a wild-type molecule containing all necessary targeting information, out of a perinuclear compartment. As reconstitution of an intact, fluorescent GFP molecule is an irreversible event (Kerppola, 2006; Kerppola, 2008) , it seems possible that complementation 'locks' the interaction of the TMDs in a manner that prevents further exit from a trans-Golgi compartment, such that only uncomplexed, tagged full-length VAMP2 molecules would go on to their intracellular vesicular destinations (supplementary material Fig. S9) .
Interestingly, BiFC between syntaxin-1A molecules was observed in an uneven manner at the plasma membrane. It remains to be determined whether this signal reflects multimers of trans SNARE complexes (Lu et al., 2008) , or clusters of SNAREs at the plasma membrane, as previously described (Lang et al., 2001; Sieber et al., 2007; Lopez et al., 2007) . Similarly, additional studies are warranted to determine whether the rather homogeneous plasma membrane BiFC signal between a syntaxin-1A and a VAMP2 molecule reflects cis SNARE complexes, or interactions between individual, non-complexed SNARE molecules.
The structure of the VAMP2 TMD in the membrane has been controversial. Initial computation and mutagenesis studies predicted that the TMD exists as a dimer with two helices oriented at a cross-2477 SNARE transmembrane domain and fusion ). The amount of hGH in the medium and in the cells was determined by an enzyme-linked immunosorbent assay, and the percentage of secreted hGH, and the total amount of hGH were calculated against an hGH standard curve. The graph is a representative of three independent experiments. Error bars indicate s.e.m. (C)Ability of different point-mutated, toxin-insensitive VAMP2 constructs to support neurosecretion in the presence of BotF/LC. Cells were transfected with a plasmid expressing hGH as well as wild-type or toxin-resistant wildtype VAMP2 (wt-r), or toxin-resistant mutant VAMP2 as indicated, permeabilised, incubated in the presence of toxin and secretion was elicited and analysed as described above. To standardise results from repeated experiments, secretion observed in the presence of toxin-insensitive wild-type VAMP2 (wt-r) was set to 100%, and the relative change of rescue of secretion of test plasmids in the presence of toxin normalised to this control. Values are means ± s.e.m. (n3). The statistical significance of differences from the wild type were analysed by Student's t-test (*P<0.05). (D)Identity of amino acid substitutions previously reported to inhibit TMD interactions in vitro. (E)BiFC with various mutant VAMP2 TMD domain constructs.
angle of 38 degrees, with residues 99, 102, 103, 107, 110 and 111 at the dimer interface (Laage and Langosch, 1997; Laage et al., 2000; Fleming and Engelman, 2001a; Roy et al., 2004) . Whereas biophysical studies on the structure of the TMD are largely confined to membrane-mimetic environments in vitro, our studies using BiFC in intact cells indicate that these residues are not sufficient to mediate TMD interactions, and are not crucial for VAMP2-mediated fusion activity.
Our data indicate an important role for a glycine residue in facilitating VAMP2 TMD interactions. Glycine is frequently found in the TMDs of membrane proteins, and has been shown to contribute to TMD dimerisation of several single-pass membrane proteins (Lemmon et al., 1994; MacKenzie et al., 1997; Burke et al., 1997; Javadpour et al., 1999; Fleming and Engelman, 2001b) . Replacement of the glycine residue with residues of increased molecular volume abolished TMD interactions, but did not interfere with neurosecretion in our toxin-rescue assay, suggesting that the TMD interactions as measured by BiFC are not necessary for the fusion activity of the v-SNARE. However, replacement of the glycine residue with a helix-distorting proline residue displayed slightly enhanced neurosecretion compared with levels in the wild type. Thus, together with other TMD mutants that displayed deficits in secretion, the observation of both inhibitory and enhancing effects on membrane fusion is indicative of a direct role for the VAMP2 TMD in exocytosis (Szule and Coorssen, 2004) .
Mutational analysis of VAMP2 further indicated that the Cterminal residues of the TMD are functionally important. It seems likely that these residues are transiently forced into close proximity at the point of membrane fusion (Tong et al., 2009 ), but our BiFC analysis might not be able to resolve such interactions on the background of fluorescence from individual, non-complexed VAMP2 molecules interacting via their TMDs. The predicted TMD of VAMP2 is unusually large, and is embedded in the membrane with a tilt with respect to the bilayer normal (Bowen and Brunger, 2006) . Thus, the TMD-mediated interaction of VAMP2 molecules identified here by BiFC probably involves a conformation whereby glycine residues oriented toward the helix-helix interface contribute to the packing of two tilted helices; however, additional transient conformations close to the point of membrane fusion might also exist.
The unstructured linker region between the SNARE motif and the TMD, which is thought to transmit the SNARE coiling energy into membrane fusion, was initially proposed to encompass residues 92-94 of VAMP2 (Kweon et al., 2003) . Deletion of those residues did not affect secretion in our assay system, indicating that the linker region is probably contributed by other residues, such as those recently described (Ellena et al., 2009) .
In the present study, we used a toxin-rescue assay to investigate SNARE-dependent membrane fusion. However, caveats of this assay are that it merely measures the extent of neurosecretion, rather than kinetic effects and/or fusion-pore phenotypes. Thus, further investigations of the mutants described here using capacitance or amperometry approaches that are able to evaluate effects on fusion-pore phenotypes are warranted.
In summary, we describe for the first time TMD-mediated interactions between VAMP2 molecules in intact cells using a BiFC approach. Glycine residues have a crucial role in TMD helix 2478 Journal of Cell Science 123 (14) Cells were transfected with a plasmid expressing hGH as well as wild-type or toxin-resistant wild-type VAMP2 (wt-r), or toxin-resistant mutant VAMP2 as indicated, permeabilised, incubated in the presence of toxin and secretion was elicited and analysed as described in legend to Fig. 4 . To standardise results from repeated experiments, secretion observed in the presence of toxin-insensitive wild-type VAMP2 (wt-r) was set to 100%, and the relative change of rescue of secretion of test plasmids in the presence of toxin normalised to this control. Values are means ± s.e.m. (n3). The statistical significance of differences from the wild type were analysed by Student's t-test (*P<0.05).
association, but such interactions do not seem to be required for efficient neurosecretion. Severe secretory deficits are observed when shortening or lengthening the C-terminal, but not the Nterminal half of the TMD, suggesting that distinct structural length requirements within the VAMP2 TMD are largely confined to the C-terminal part. It is thus tempting to speculate that the conformation of the C-terminal part of the VAMP2 TMD, which can be further modulated by the lipid environment (Tong et al., 2009; Chang et al., 2009) , might regulate the formation of a hemifusion state (Chernomordik and Kozlov, 2005; Xu et al., 2005; Hofmann et al., 2006; Wong et al., 2007; Lu et al., 2008; Liu et al., 2008; Chang et al., 2009 ) en route to full membrane merging.
Materials and Methods
Plasmid constructs and site-directed mutagenesis
For secretion assays, full-length, non-tagged rat VAMP2 (residues 1-116) was expressed from a pCMV-driven promoter in a vector where expression of hGH is driven from an SV40 promoter (pCMV5-VAMP2-SV40-hGH) (Fdez et al., 2008) . C-terminally GFP-tagged VAMP2 was generated by subcloning full-length VAMP2 into a pGFPemd vector (Packard) using the EcoRI-BamHI sites, with a resulting linker (TDPPVAT) between the VAMP2 and the GFP sequences. GFP-tagged constructs were also generated whereby VAMP2 was subcloned into the EGFP-C1 vector (Clontech) using the HindIII-BamHI sites to generate an N-terminal GFPfusion protein. C-terminally GFP-tagged syntaxin-1A was generated by subcloning the sequence encoding full-length syntaxin-1A into a pGFPemd vector (Packard) using the EcoRI-HindIII sites, with a resulting linker (KLAVPRARDPPVAT) between the syntaxin-1A and the GFP sequences. N-terminally GFP-tagged syntaxin-1A was a generous gift from George Augustine (Duke University, Durham, NC).
Site-directed mutagenesis was performed using the QuikChange Site-Directed Mutagenesis Kit (Stratagene) according to manufacturer's instructions. To generate the VAMP2 BiFC constructs, a linker (SGGSGGTVGSR) was generated at the Cterminus of VAMP2 in the pCMV5-VAMP2-SV40-hGH construct using site-directed mutagenesis. The two halves of Venus (VenusN, VenusC, were then PCR amplified from a full-length construct, digested and cloned in-frame with the linker using the XbaI-BamHI sites.
VAMP2-VenusN was PCR amplified and subcloned into pCMV-HA (Clontech) using the EcoRI-XhoI sites to generate an N-terminally HA-tagged construct, and VAMP2-VenusC was PCR amplified and subcloned into pCMV-myc (Clontech) using the EcoRI-XhoI sites to generate an N-terminally myc-tagged construct, respectively. To generate the syntaxin-1A BiFC constructs, cDNA encoding syntaxin-1A was PCR amplified and cloned into the VAMP2 BiFC vectors using EcoRI, thereby replacing the VAMP2 sequence with the syntaxin-1A sequence. To generate the synaptotagmin-1 BiFC constructs, the sequence encoding full-length synaptotagmin-1 was PCR amplified and cloned into the syntaxin-1A BiFC vectors using XbaI and BamHI, thereby replacing the syntaxin-1A sequence by the synaptotagmin-1 sequence. Control constructs expressing only the two individual halves of Venus were generated by deleting VAMP2 from the VAMP2 BiFC constructs by prior introduction of an EcoRI site at the C-terminus of VAMP2 using site-directed mutagenesis, followed by digestion with EcoRI and re-ligation. The VAM21-78 deletion constructs were generated by introducing an EcoRI site at position E78, followed by digestion with EcoRI and re-ligation. The VAMP2-TMD constructs were generated by introducing an EcoRI site at position W90, followed by digestion with EcoRI and re-ligation. All other mutant VAMP2 constructs were generated using site-directed mutagenesis. All constructs were verified by DNA sequencing. The sequences of primers used in this study are available upon request.
PC12 cell culture, transfection and imaging
PC12 cells were grown and transfected essentially as described (Fdez et al., 2008) . Double transfections were performed with each 2.4 g DNA using 10 l LipofectAMINE 2000 (Invitrogen). Cells were grown for 3 days either in full medium (non-differentiated) or in serum-reduced medium (1%) containing 50 ng/ml NGF 2.5 S (Invitrogen) (differentiated). Cells were examined either live, or upon fixation (Fdez et al., 2008) and mounting (ProLong-Gold antifade reagent, Invitrogen). For colocalisation analysis, the following antibodies were used: rabbit polyclonal antisynaptotagmin (p65, 1:1000) (Fdez et al., 2008) , mouse monoclonal anti-VAMP2 (Cl 69.1, Synaptic Systems, 1:5000), mouse monoclonal anti-rat TGN38 (BD Biosciences, 1:800), rabbit polyclonal anti-calnexin (Stressgen, SPA860, 1:300), mouse monoclonal anti-syntaxin-(CL HPC-1, SIGMA, 1:500), mouse monoclonal anti-TfR (Invitrogen, 1:300), mouse monoclonal anti-EEA1 (BD Biosciences, 1:250), mouse monoclonal anti-synaptophysin (CL SVP38, Sigma, 1:200), mouse monoclonal anti-GM130 (BD Biosciences, 1:100) and rabbit polyclonal anti-GFP (Abcam, 1:500). Secondary antibodies included Alexa Fluor 594-conjugated goat anti-mouse (Invitrogen, 1:1000) and Alexa Fluor 594-conjugated goat anti-rabbit (Invitrogen, 1:1000).
Images were acquired on a Leica TCS-SP5 confocal microscope using a 63ϫ 1.4 NA oil UV objective (HCX PL APO CS). Images were collected using single excitation for each wavelength separately (488 nm Argon Laser line and a 500-545 nm emission band pass; 543 nm HeNe Laser line and a 556-673 nm emission band pass). 10-15 image sections of selected areas were acquired with a step size of 0.3 m, and z-stack images analysed and processed using Leica Applied Systems (LAS AF6000) image acquisition software. For quantification of co-localisation, three independent, nonsaturated z-stack images were analysed for each condition, whereby a fixed area of interest of 36 m 2 was chosen to determine co-localisation in neuritic processes, adjusting thresholds to 28% for each channel. Co-localisation rates were obtained using Leica Applied Systems (LAS AF6000) image-acquisition software. Overexpression levels were determined as previously described (Fdez et al., 2008) . For co-localisation of the BiFC signal with wild-type or mutant myc-VAMP2-VenusC and HA-VAMP2-VenusN constructs, transfected cells were processed as described above, and incubated with a mouse monoclonal anti-myc antibody (Sigma, clone 9E10, 1:500) and a rabbit polyclonal anti-HA antibody (Abcam, ab9110, 1:200) . Secondary antibodies included Alexa Fluor 405-conjugated goat anti-mouse (Invitrogen, 1:100) and Alexa Fluor 594-conjugated goat anti-rabbit (Invitrogen, 1:1000). Images were acquired sequentially using the 488 nm and 594 nm lasers to detect the BiFC signal and the HA staining, and a UV diode (405 nm UV diode and 422-466 nm emission band pass) (12.5% intensity) to detect the myc signal. The same laser intensity was used for comparison between wild-type and mutant constructs.
For live-cell imaging, cells were monitored on an Olympus microscope (Cell R IX81) using a 40ϫ objective and an MT20 illumination system with Orca CCD camera (Hamamatsu) in a chamber at 37°C and 5% CO 2 using a Solent scientific CO 2 enrichment and temperature system.
Toxin-rescue assays
Recombinantly expressed endopeptidase light chain of botulinum neurotoxin serotype F (botF/LC) was used for toxin-rescue assays. BotF/LC was expressed in BL21(DE3) E. coli as a fusion protein comprising N-terminal maltose-binding protein (MBP) and C-terminal 6ϫ-His tags. The protein was purified by binding to a Ni affinitychromatography column equilibrated in lysis buffer (50 mM HEPES, 200 mM NaCl, pH 7.2) and eluted with a step gradient of 20, 40, 100 and 200 mM imidazole in lysis buffer. The bulk of the protein eluted in the 100 mM step. This material was pooled (40 ml), dialysed against lysis buffer (three changes of 600 ml each at 4°C) and then frozen as aliquots (-20°C). The protein concentration was determined from the absorbance reading at 280 nm.
The endopeptidase activity of purified botF/LC was measured against a purified recombinant substrate (VAMP2-96-GFP). Endopeptidase-activity assays were performed in assay buffer (50 mM HEPES, 0.02 mM ZnCl 2 , 0.1 mg/ml BSA) with 0.004 mM substrate and two different concentrations of botF/LC (11 and 53 nM) at 37°C for 1 hour. Cleaved substrate was measured by densitometry of stained SDS-PAGE gels and quantified against BSA standards run on the same gel. The specific activity of the preparation was 55 pmol VAMP2-96-GFP cleaved/hour/pmol enzyme. Determination of the cleavage of endogenous VAMP2 in PC12 cells upon toxin treatment was performed as described (Fdez et al., 2008) in the presence of 150 g botF/LC. Release of hGH from toxin-treated, permeabilised PC12 cells transfected with botF-resistant VAMP2 (K59R) was measured as described (Fdez et al., 2008) in the presence of 35 l/well of recombinant botF/LC.
Cell extracts and immunoblotting
Transfected PC12 cells were washed three times with wash buffer (156 mM NaCl, 5.6 mM KCl, 5.6 mM glucose, 0.2 mM EGTA, 5 mM HEPES, pH 7.4), permeabilised for 5 minutes in KGEP10 buffer (10 M digitonin, 140 mM K-glutamate, 5 mM glucose, 5 mM EGTA, 100 M ZnCl 2 , 20 mM PIPES, pH 6.8) and incubated in KGEP10 buffer containing 35 l/well botF/LC for 20 minutes at 37°C. Cells were subsequently washed for 10 minutes with wash buffer and collected in buffer containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 10 mM EDTA, 1% Tx-100 and 1 mM PMSF. Cell extracts were resolved on 15% polyacrylamide gels, VAMP2 was detected with a mouse monoclonal anti-VAMP2 antibody (clone C110.1; 1:1500; Synaptic Systems), and to confirm equal amounts of protein loading, membranes were subsequently blotted with a mouse monoclonal anti-synaptophysin antibody (clone SVP38; 1:500; Sigma). For determination of co-expression of synaptotagmin BiFC constructs, cell extracts (40 g) were resolved on 12.5% SDS-PAGE gels, and endogenous, VenusNor VenusC-tagged synaptotagmin-1 detected by a rabbit polyclonal antibody (p65, 1:1000) (Fdez et al., 2008) . As the VAMP2-VenusN and VAMP2-VenusC constructs were not recognised by either anti-VAMP2 or anti-GFP antibodies on western blots, we generated wild-type and mutant HA-VAMP2-VenusN and myc-VAMP2-VenusC constructs. Cells were co-transfected with those constructs, and extracts (40 g) resolved by 12.5% SDS-PAGE, followed by blotting with a mouse monoclonal antimyc antibody (Sigma, 1:500) or a rabbit polyclonal anti-HA antibody (Sigma, 1:500). Anti-myc signal was detected with LumiLight western blotting substrate (Roche), and the anti-HA signal with ECL Advance western blotting substrate (GEHealthcare).
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